Trimethidinium methosulfate | 14149-43-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 英文名称: Trimethidinium methosulfate
• 英文别名: methyl sulfate;trimethyl-[3-(1,3,8,8-tetramethyl-3-azoniabicyclo[3.2.1]octan-3-yl)propyl]azanium
• CAS: 14149-43-0
• 化学式: C19H42N2O8S2
• 分子量: 490.7
• InChiKey: ZOSQTCOGKFRDET-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  1.17
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  150
• 氢给体数：
  0
• 氢受体数：
  8

文献信息

• [EN] INHIBITORS OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE FOR TREATING CARDIOVASCULAR AND PULMONARY CONDITIONS<br/>[FR] INHIBITEURS DE LA GLUCOSE-6-PHOSPHATE DÉSHYDROGÉNASE PERMETTANT DE TRAITER DES AFFECTIONS CARDIOVASCULAIRES ET PULMONAIRES
  申请人：GUPTE SACHIN A

  公开号：WO2018093856A1

  公开（公告）日：2018-05-24

  The present disclosure provides for methods of treating or preventing a cardiovascular disorder and/or a related pulmonary disorder in a subject. In certain embodiments, the method comprises administering a therapeutically effective amount of an inhibitor of Glucose-6-phosphate dehydrogenase (G6PD), or a pharmaceutically acceptable salt, non-salt amorphous form, solvate, poly-morph, tautomer or prodrug thereof.

  本公开提供了用于治疗或预防受试者的心血管疾病和/或相关肺部疾病的方法。在某些实施例中，该方法包括向受试者投予治疗有效量的葡萄糖-6-磷酸脱氢酶（G6PD）抑制剂，或其药用可接受的盐、非盐非晶形态、溶剂合物、多形态、互变异构体或前药。
• Compositions and Methods for Cellular Imaging and Therapy
  申请人：Yang J. David

  公开号：US20070248537A1

  公开（公告）日：2007-10-25

  The present invention relates generally to the fields of chemistry and radionuclide imaging. More particularly, it concerns compositions, kits and methods for imaging and therapy involving N 4 compounds and derivatives.

  本发明一般涉及化学和放射性核素成像领域。更具体地，涉及涉及N4化合物及其衍生物的成分、试剂盒和成像和治疗方法。
• [EN] (S) - ENOXIMONE SULFOXIDE AND ITS USE IN THE TREATMENT OF PDE-III MEDIATED DISEASES<br/>[FR] SULFOXYDE DE (S)-ENOXIMONE ET SON UTILISATION DANS LE TRAITEMENT DE MALADIES MEDIEES PAR PDE-III
  申请人：MYOGEN INC

  公开号：WO2005092332A1

  公开（公告）日：2005-10-06

  The present invention provides the (S)-(-) enoximone sulfoxide enantiomer, as well as pharmaceutical formulations of the purified (S)-(-) sulfoxide enantiomer. Also provided are methods of treating diseases in which inhibition of PDE-III may be beneficial.

  本发明提供了（S）-（-）恩奥西莫酮亚砜对映体，以及纯化的（S）-（-）亚砜对映体的药物配方。还提供了在其中抑制PDE-III可能有益的治疗疾病的方法。
• [EN] (R)-ENOXIMONE SULFOXIDE AND ITS USE IN THE TREATMENT OF PDE-III MEDIATED DISEASES<br/>[FR] (R)-ENOXIMONE SULFOXYDE ET SON UTILISATION DANS LE TRAITEMENT DE MALADIES INDUITES PAR PDE-III
  申请人：MYOGEN INC

  公开号：WO2005092333A1

  公开（公告）日：2005-10-06

  The present invention provides the (R)-(+) enoximone sulfoxide enantiomer, as well as pharmaceutical formulations of the purified (R)-(+) sulfoxide enantiomer. Also provided are methods of treating diseases in which inhibition of PDE-III may be beneficial.

  本发明提供了（R）-（+）羟亚胺磺酰氧化物对映体，以及纯化的（R）-（+）磺酰氧化物对映体的药物配方。还提供了在其中抑制PDE-III可能有益的治疗疾病的方法。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。